Naitoh N, Furushima H, Ohira K, Taneda K, Aizawa Y
First Department of Internal Medicine, Niigata University School of Medicine, Japan.
Jpn Heart J. 1998 Mar;39(2):153-61. doi: 10.1536/ihj.39.153.
The interaction between dl-sotalol and isoproterenol on the ventricular effective refractory period (VERP) and conduction were examined in an electrophysiologic study of 9 patients at drug-free baseline, after 14 days of dl-sotalol administration (320 mg/day), and after the administration of isoproterenol. In all 9 patients, ventricular tachyarrhythmia could not be induced after dl-sotalol treatment. Isoproterenol was administered as a loading dosage of 0.025 microgram/kg for 5 min with a maintenance dosage of 0.0025 microgram/kg/min. The VERP and the QRS duration were determined at paced cycle lengths of 600, 400 and 300 msec. DL-sotalol and dl-sotalol + isoproterenol had no effect on ventricular conduction at the three cycle lengths. The VERP was significantly prolonged after dl-sotalol treatment at paced cycle lengths of 600 (241 +/- 16 to 302 +/- 28 msec, p < 0.001), 400 (223 +/- 21 to 280 +/- 23 msec, p < 0.001) and 300 msec (202 +/- 16 to 256 +/- 24 msec, p < 0.005), but there was a parallel shift of the VERP, suggesting the absence of use-dependent effects on the VERP. The dl-sotalol-induced VERP prolongation was partially reversed by isoproterenol, but it remained significantly prolonged above baseline values at paced cycle lengths of 600 (241 +/- 16 to 281 +/- 18 msec, p < 0.01), 400 (223 +/- 21 to 258 +/- 20 msec, p < 0.01) and 300 msec (202 +/- 16 to 247 +/- 22 msec, p < 0.01). The shortening of the VERP was greater at longer basic cycle lengths (600 and 400 msec) than at the shorter paced cycle length (300 msec, p < .05), but the percentage increase of the VERP was similar at the three basic cycle lengths of 600 (16%), 400 (15%) and 300 (20%) msec, indicating the lack of reverse use-dependency. The absence of reverse use-dependency of dl-sotalol on the VERP, even after isoproterenol administration, may be beneficial in the therapy of ventricular tachyarrhythmias and may account in part for the high efficacy of this drug.
在一项电生理研究中,对9例患者在无药基线状态、给予dl - 索他洛尔(320毫克/天,持续14天)后以及给予异丙肾上腺素后,研究了dl - 索他洛尔与异丙肾上腺素对心室有效不应期(VERP)和传导的相互作用。在所有9例患者中,dl - 索他洛尔治疗后不能诱发室性快速心律失常。异丙肾上腺素以0.025微克/千克的负荷剂量给药5分钟,维持剂量为0.0025微克/千克/分钟。在起搏周期长度为600、400和300毫秒时测定VERP和QRS时限。DL - 索他洛尔和dl - 索他洛尔 + 异丙肾上腺素在这三个周期长度下对心室传导均无影响。在起搏周期长度为600(241±16至302±28毫秒,p < 0.001)、400(223±21至280±23毫秒,p < 0.001)和300毫秒(202±16至256±24毫秒,p < 0.005)时,dl - 索他洛尔治疗后VERP显著延长,但VERP呈平行移位,提示对VERP不存在使用依赖性效应。dl - 索他洛尔所致的VERP延长被异丙肾上腺素部分逆转,但在起搏周期长度为600(241±16至281±18毫秒,p < 0.01)、400(223±21至258±20毫秒,p < 0.01)和300毫秒(202±16至247±22毫秒,p < 0.01)时仍显著长于基线值。在较长的基础周期长度(600和400毫秒)时VERP的缩短幅度大于较短的起搏周期长度(300毫秒,p < 0.05),但在600(16%)、400(15%)和300(20%)毫秒这三个基础周期长度下VERP的增加百分比相似,表明不存在反向使用依赖性。即使在给予异丙肾上腺素后,dl - 索他洛尔对VERP不存在反向使用依赖性,这在室性快速心律失常的治疗中可能是有益的,并且可能部分解释了该药物的高疗效。